Effect of the PI3K-AKT-mTOR pathway on the drug resistance of osteosarcoma cells and its mechanism
孙亮,郭世炳,赵伟,娜日松,王玉鑫,赵振群
DOI: https://doi.org/10.3760/cma.j.cn101202-20200315-00082
2021-01-01
Abstract:Objective:This study aims to investigate the effect of the phosphatidylinositol 3-hydroxy kinase(PI3K)-protein kinase B(AKT)-mammalian target of rapamycin(mTOR) pathway on the drug resistance of osteosarcoma cells and its mechanism to provide new ideas for the targeted therapy of osteosarcoma.Methods:MG-63 cells were cultured in vitro, and MG-63 drug-resistant cell lines were established using the repeated administration of 2 μg/mL cisplatin. The high-expression plasmids of miRNA-22 were transfected into MG-63 drug-resistant cell lines to establish MG-63 drug-resistant cell lines with high miRNA-22 expression. MG-63 cells were the control group, and the MG-63 drug-resistant cells were the drug-resistant group. MG-63 frug-resistant cells treated with 2 μg/mL cisplatin and the drug-resistant MG-63 cells transfected with miRNA-22 were the drug-resistant DDP and the drug-resistant miRNA-22+ DDP groups, respectively. The cell proliferation was detected using the thiazoline (MTT) assay. The expression levels of PI3K, AKT, and mTOR mRNA were detected using fluorescence quantitative RT-PCR. The protein expressions of PI3K, AKT, pAKT, mTOR, and p-mTOR were detected using the Western blot.Results:(1)The MTT results showed that the absorbance values of the control, drug-resistant, drug-resistant DDP, and drug-resistant miRNA-22+ DDP groups were 1.097±0.039, 1.157±0.065, 0.870±0.014, and 0.737±0.029, respectively. The differences were statistically significant ( F=67.731, P<0.01). Compared with that of the control group, the absorbance of the drug-resistant DDP and the drug-resistant miRNA-22+ DDP groups decreased significantly (all P values<0.01). For the drug-resistant, drug-resistant DDP group, and drug-resistant miRNA-22+ DDP group, the absorbance showed a downward trend, and the differences were statistically significant (all P values<0.01). (2)The results of fluorescence quantitative RT-PCR showed that compared with that in the control group, the relative expression of PI3K and AKT in the drug-resistant and the drug-resistant DDP groups increased especially in the drug-resistant group (all P values<0.01). No significant difference was observed between the drug-resistant miRNA-22+ DDP and the control groups (all P values>0.01). The relative expression of mTOR significantly increased in the drug-resistant group and significantly decreased in the drug-resistant DDP and the drug-resistant miRNA-22+ DDP groups (all P values<0.01). The relative expression levels of PI3K, AKT, and mTOR in the drug-resistant DDP and drug-resistant miRNA-22+ DDP groups were lower than those in the drug-resistant group, and all differences were statistically significant (all P values<0.01). The relative expression levels of PI3K and mTOR in the drug-resistant miRNA-22+ DDP group were lower than those in the drug-resistant DDP group, and the differences were statistically significant (all P values<0.01). (3) The results of Western blot showed that compared with that in the control group, the relative expression levels of PI3K, AKT, and mTOR proteins in the drug-resistant group increased significantly and that the relative expression levels of PI3K and AKT proteins in the drug-resistant DDP and drug-resistant miRNA-22+ DDP groups were significantly reduced. The differences were statistically significant (all P values<0.01). The pairwise comparison among three groups revealed that the relative expression levels of PI3K, AKT, and mTOR proteins in the drug-resistant DDP and drug-resistant miRNA-22+ DDP groups were significantly lower than those in the drug-resistant group. The relative expression levels of PI3K and AKT proteins in the drug-resistant miRNA-22+ DDP group were significantly lower than those in the drug-resistant DDP group (all P values<0.01). Conclusions:The PI3K-AKT-mTOR pathway was involved in the development of osteosarcoma cells' resistance to cisplatin. miRNA-22 reduced the resistance of osteosarcoma cells to cisplatin by downregulating the expression levels of PI3K, AKT, and mTOR in the PI3K-AKT-mTOR pathway.